The News Review:
- Health & Fitness : Synergy Research Group and Promedica Internatio…
- INSTITUTE F CLINICAL RESEARCH (INDIA) NEW DELHI
- Inching closer
- Retired YSU professor stays focused on research
- Atom-sized solution to cut cancer drug toxicity
- Blood Substitute Trial Shows No Survival Advantage To Trauma Patients
Health & Fitness : Synergy Research Group and Promedica Internatio…
skynewswire.com – Nov 3, 2007
The company?s headquarters are in Moscow. About Promedica InternationalPromedica International (PMI) is a privately held corporation with headquarters located in Costa Mesa California. Founded in 1985 the company provides specialized clinical research services to the medical device biotech and pharmaceutical industries. IS 9001:2000 certified and servicing a range of medical specialties and therapeutic areas the company has extensive experience in clinical study service projects and has provided support for studies evaluating a variety of medical specialty treatments.
INSTITUTE F CLINICAL RESEARCH (INDIA) NEW DELHI
Calcutta Telegraph – Nov 3, 2007
ELIGIBILITY: Diploma or certificate holders in nursing can apply for admission. PARTICULARS: The prospectus and application form will be available on payment of Rs 300 in cash or by sending a demand draft drawn in favour of Institute of Clinical Research (India) by courier to the institute. Details can also be obtained by sending an e-mail to enquiry@icriindia.
Inching closer
guardian.co.uk – Nov 3, 2007
We have learned a great deal about HIV – arguably more than about any other pathogen – and about its interaction with our immune system. nly in recent years have scientists from around the world begun to collaborate to turn this knowledge into novel designs for HIV vaccine candidates. Importantly developing countries are playing a crucial role in this effort following significant investment there in the infrastructure scientists and technicians necessary to conduct clinical research. With 33 million people living with HIV around the world and 2. 5 million newly infected last year it is clear that existing interventions are not successfully controlling this pandemic especially not in developing countries which account for 95% of new infections. Investing in Aids vaccine research is investing in an opportunity not just to ameliorate the suffering caused by Aids but to actually end the epidemic. Certainly that investment should not be at the expense of scaling up access to proven prevention strategies or of delivering much needed medication to people infected with HIV.
Retired YSU professor stays focused on research
Youngstown Vindicator – Nov 3, 2007
Del Bene received YSU?s Heritage Award in 2003 and the Dean?s Lifetime Achievement Award for Externally Supported Research in 2003. She was given the National Honorary Member Award for an utstanding Woman Chemist from Iota Sigma Pi in 2002 and she received a Director?s Award for her 2002 National Science Foundation grant. She is a 22-year member of the Clinical Research Committee of St. Elizabeth Health Center and has been a consultant to Goodyear and the National Institutes of Health and an external examiner for the Department of Energy. CommentsRequires free registration. Username: Password: (Forgotten your password?)Comment:.
Atom-sized solution to cut cancer drug toxicity
Inquirer.net – Nov 3, 2007
Emerging ‘targeted therapy’In cancer treatment nanotechnology belongs to the emerging “targeted therapy” which in theory would bring the fight against cancer to the molecular level (ferrying large doses of chemotherapeutic agents into malignant cells while sparing healthy cells) thus eliminating “collateral damage” to noncancerous cells and also eliminating the toxicity of the drug on the patient as a whole. Shiva Kant Mishra vice president for Dabur Research Foundation’s clinical research and medical services said nanopaclitaxel uses a polymer compound to convert the drug into its nano-sized molecules. “The polymer basically holds the molecule from all the sides and takes it everywhere. It’s like a nanopack pocket. Dabur began its project eight years ago after licensing a nanopolymer base from Delhi University. During the Dabur Pharma-Philippine Society for Medical ncology symposium Mishra discussed that since its launch in India in January 2007 Nanoparticle paclitaxel (Nanoxel) has been administered to more than 900 patients.
Blood Substitute Trial Shows No Survival Advantage To Trauma Patients
emaxhealth.com – Nov 3, 2007
Before beginning the trial each center conducted a series of information sessions and other educational efforts throughout the community describing the details of the trial. Residents who did not want to participate in the research study were instructed to notify the study site to "opt out. "Nationwide a total of 714 patients were enrolled in the trial – 350 were randomized to receive PolyHeme and 364 were randomized to the standard of care group. The trial was intended to determine whether or not PolyHeme was better than the traditional treatment.
